210 related articles for article (PubMed ID: 24287458)
21. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.
Hoot AC; Russo P; Judkins AR; Perlman EJ; Biegel JA
Am J Surg Pathol; 2004 Nov; 28(11):1485-91. PubMed ID: 15489652
[TBL] [Abstract][Full Text] [Related]
22. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
Rizzo D; Fréneaux P; Brisse H; Louvrier C; Lequin D; Nicolas A; Ranchère D; Verkarre V; Jouvet A; Dufour C; Edan C; Stéphan JL; Orbach D; Sarnacki S; Pierron G; Parfait B; Peuchmaur M; Delattre O; Bourdeaut F
Am J Surg Pathol; 2012 Jul; 36(7):964-72. PubMed ID: 22614000
[TBL] [Abstract][Full Text] [Related]
23. Intra-articular epithelioid sarcoma showing mixed classic and proximal-type features: report of 2 cases, with immunohistochemical and molecular cytogenetic INI-1 study.
Kosemehmetoglu K; Kaygusuz G; Bahrami A; Raimondi SC; Kilicarslan K; Yildiz Y; Folpe AL
Am J Surg Pathol; 2011 Jun; 35(6):891-7. PubMed ID: 21566521
[TBL] [Abstract][Full Text] [Related]
24. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.
Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M
J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366
[TBL] [Abstract][Full Text] [Related]
25. Utility of characteristic 'Weak to Absent' INI1/SMARCB1/BAF47 expression in diagnosis of synovial sarcomas.
Rekhi B; Vogel U
APMIS; 2015 Jul; 123(7):618-28. PubMed ID: 25912315
[TBL] [Abstract][Full Text] [Related]
26. Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features.
Kohashi K; Tanaka Y; Kishimoto H; Yamamoto H; Yamada Y; Taguchi T; Iwamoto Y; Oda Y
Mod Pathol; 2016 Oct; 29(10):1232-42. PubMed ID: 27338635
[TBL] [Abstract][Full Text] [Related]
27. [Molecular genetics and immunophenotype of INI1/SMARCB in epithelioid sarcoma].
Li L; Xia Q; Rao Q; Liu B; Wu B; Shi S; Yu B; Zhang R; Lu Z; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):389-93. PubMed ID: 25208989
[TBL] [Abstract][Full Text] [Related]
28. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
29. Prognostic determinants in epithelioid sarcoma.
Gasparini P; Facchinetti F; Boeri M; Lorenzetto E; Livio A; Gronchi A; Ferrari A; Massimino M; Spreafico F; Giangaspero F; Forni M; Maestro R; Alaggio R; Pilotti S; Collini P; Modena P; Sozzi G
Eur J Cancer; 2011 Jan; 47(2):287-95. PubMed ID: 20932739
[TBL] [Abstract][Full Text] [Related]
30. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.
Schaefer IM; Agaimy A; Fletcher CD; Hornick JL
Mod Pathol; 2017 Apr; 30(4):539-548. PubMed ID: 28084340
[TBL] [Abstract][Full Text] [Related]
31. INI1-deficient tumors: diagnostic features and molecular genetics.
Hollmann TJ; Hornick JL
Am J Surg Pathol; 2011 Oct; 35(10):e47-63. PubMed ID: 21934399
[TBL] [Abstract][Full Text] [Related]
32. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
33. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
34. Non-linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome.
Frühwald MC; Hasselblatt M; Wirth S; Köhler G; Schneppenheim R; Subero JI; Siebert R; Kordes U; Jürgens H; Vormoor J
Pediatr Blood Cancer; 2006 Sep; 47(3):273-8. PubMed ID: 16206192
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Iwasaki H; Sonobe H; Goto H; Kusakabe H; Takahira T; Kobayashi C; Kawaguchi K; Saito T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2006 Jun; 19(6):820-31. PubMed ID: 16557275
[TBL] [Abstract][Full Text] [Related]
36. Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1.
Frank R; Sadri N; Bhatti T; Biegel JA; Livolsi VA; Zhang PJ
J Clin Exp Oncol; 2013; 2(2):. PubMed ID: 24308011
[TBL] [Abstract][Full Text] [Related]
37. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
Bourdeaut F; Chi SN; Frühwald MC
Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
[TBL] [Abstract][Full Text] [Related]
38. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Hornick JL; Dal Cin P; Fletcher CD
Am J Surg Pathol; 2009 Apr; 33(4):542-50. PubMed ID: 19033866
[TBL] [Abstract][Full Text] [Related]
39. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.
Eaton KW; Tooke LS; Wainwright LM; Judkins AR; Biegel JA
Pediatr Blood Cancer; 2011 Jan; 56(1):7-15. PubMed ID: 21108436
[TBL] [Abstract][Full Text] [Related]
40. Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA.
Zhang K; Gao H; Wu X; Wang J; Zhou W; Sun G; Wang J; Wang Y; Mu B; Kim C; Chu P; Ho DM; Ann DK; Wong TT; Yen Y
Clin Cancer Res; 2014 Mar; 20(5):1179-89. PubMed ID: 24423609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
